Abbisko Therapeutics enters global tie-up with Lilly to develop novel molecules
The tie-up combines Abbisko Therapeutics’ proprietary drug discovery platform with Lilly’s disease and discovery expertise
The tie-up combines Abbisko Therapeutics’ proprietary drug discovery platform with Lilly’s disease and discovery expertise
Extending nonsurgical treatment options for Failing Pulmonic Valve in patients with congenital heart disease using Transcatheter Pulmonary Valve
Results from the BiologyWorks k(now) molecular test were 99.1% in overall percent agreement with the results of the RT-PCR lab tests
The global multi-center phase-II clinical trial will be a 36-week, multi-center, randomized, double-blind, placebo-controlled trial, followed by a 36-week open-label extension period
Occupancy is expected to be in the range of 60-62% while Average Revenue Per Occupied Bed (ARPOB) is expected to expand by least 6% in FY2022
Their strong recommendation is based on moderate certainty evidence that it improves survival and reduces the need for ventilation
Market data indicates that more than twenty percent of the new chemical entities being developed use roller compaction technology in their development and commercialization
The new plant at Slovenská ?up?a site in Slovakia is scheduled to come on stream in two years
Three Indian firms namely Curisin, Immunidex and Telemedicine Indian company are part of the first phase
The new collaboration focuses on a class of proteins called transcription factors, which control gene expression and can regulate important cellular processes including cell growth and survival
Subscribe To Our Newsletter & Stay Updated